MiNK Therapeutics Initiates Phase 2 Trial for agenT-797 in Acute Lung Injury, Reports Q1 2026 Results and Advances iNKT Cell Therapy Platform
MiNK Therapeutics Reports Q1 2026 Results: Advances in iNKT ...
Sign in to continue:
MiNK Therapeutics Reports Q1 2026 Results: Advances in iNKT ...
ContextLogic Holdings Inc. Reports Q1 2026 Financial Results...
PAVmed Reports Q1 2026 Results and Provides Business Update ...
BioCardia, Inc. Reports First Quarter 2026 Business Highligh...
Repligen Corporation Announces Results of 2026 Annual Shareh...
Datavault AI Inc. Q1 2026 Business Update: Surging Revenues,...
1847 Holdings LLC Q1 2026 Financial Results: Key Takeaways f...
Safe Pro Group Inc. (NASDAQ: SPAI) Reports Record-Breaking Q...
Pulmatrix Q1 2026 Financial Results & Merger Update Pu...
Buda Juice (NYSE American: BUDA) Delivers Strong Q1 2026 Res...